by Sara M. Nolte | Sep 28, 2015
. Much of what we discuss here on Signals is what’s going on in the lab. I’ve definitely done my share of promoting basic science research in the cancer stem cell field (here and here). By now you, and almost everyone else, must be wondering why these “wonder drugs”...
by Stacey Johnson | Sep 4, 2015
. It’s September. I can almost hear the school bells ringing. I can definitely feel excitement in the air. For many, back to school isn’t something to dread: just the opposite; it’s something to get excited about. Tests and homework and waking up early aren’t much...
by Mark Curtis | Aug 25, 2015
. Welcome to your update from the Clinic for the month of July. Adaptimmune moves a second candidate into the clinic. Ziopharm receives an Orphan Drug Designation for its cutting edge IL-12 technology. Canadian cell therapy company, Hemostemix, keeps moving forward...
by Mark Curtis | Aug 18, 2015
. Welcome to your Cell Therapy Deal Review for the month of July. Here at Signals we’ve decided to change the name of this monthly column, to pay consideration to the fact the majority of the technologies discussed here are cell-based. Moving forward, I will continue...
by Stacey Johnson | Aug 14, 2015
. Do you listen to The Stem Cell Podcast? If not, why not? Last September, former Signals co-editor Lisa Willemse blogged about the podcast, which, at the time, was celebrating its first anniversary. The hosts and creators behind the podcast are celebrating another...
Comments